Richard Davies
Direktor/Vorstandsmitglied bei ALVOTECH
Vermögen: 16 Mio $ am 30.04.2024
Profil
Richard John Davies is currently the Chief Executive Officer at Auregen Biotherapeutics SA and Auregen Biotherapeutics, Inc. He is also the Chairman at Immodulon Therapeutics Ltd.
and Bone Support Incentive AB.
Additionally, he serves as the Deputy Chairman at Alvotech hf and Alvotech.
In his former positions, Mr. Davies was the Chief Executive Officer at BONESUPPORT HOLDING AB and BONE SUPPORT AB from 2016 to 2018.
He also held the role of Vice President & General Manager-Asia Pacific at Amgen, Inc. from 2003 to 2012.
Furthermore, he was the General Manager-Poland & Baltics at Eli Lilly & Co. and the Chief Commercial Officer & Senior Vice President at Hospira, Inc. from 2012 to 2015.
Mr. Davies was also the Vice President & General Manager at Amgen KK in 2011 and the General Manager at Amgen Australia Pty Ltd.
in 2007.
Mr. Davies obtained an MBA from the University of Warwick and an undergraduate degree from the University of Portsmouth.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ALVOTECH
0,43% | 15.02.2024 | 1 143 713 ( 0,43% ) | 16 Mio $ | 30.04.2024 |
Aktive Positionen von Richard Davies
| Unternehmen | Position | Beginn |
|---|---|---|
| ALVOTECH | Direktor/Vorstandsmitglied | 01.01.2019 |
Bone Support Incentive AB
 Bone Support Incentive AB Real Estate DevelopmentFinance Part of BONESUPPORT HOLDING AB, Bone Support Incentive AB provides real estate services. The company is based in Lund, Sweden. | Vorsitzender | - |
Alvotech hf
 Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | Direktor/Vorstandsmitglied | 01.01.2016 |
Auregen Biotherapeutics SA
 Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | Vorstandsvorsitzender | 20.11.2018 |
Auregen Biotherapeutics, Inc.
 Auregen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auregen Biotherapeutics, Inc. provides biotechnology services. The CEO of the American company is Richard John Davies. | Vorstandsvorsitzender | - |
Immodulon Therapeutics Ltd.
 Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Vorsitzender | 10.05.2023 |
Ehemalige bekannte Positionen von Richard Davies
| Unternehmen | Position | Ende |
|---|---|---|
| BONESUPPORT HOLDING AB | Vorstandsvorsitzender | 01.03.2018 |
BONE SUPPORT AB
 BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | Vorstandsvorsitzender | 01.01.2018 |
| HOSPIRA, INC. | Corporate Officer/Principal | 01.01.2015 |
| ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Richard Davies
| University of Portsmouth | Undergraduate Degree |
| University of Warwick | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| BONESUPPORT HOLDING AB | Health Technology |
| ALVOTECH | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Hospira, Inc.
 Hospira, Inc. Pharmaceuticals: MajorHealth Technology Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL. | Health Technology |
Amgen KK
 Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million. | Health Technology |
| Amgen Australia Pty Ltd. | |
BONE SUPPORT AB
BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | Health Technology |
Bone Support Incentive AB
Bone Support Incentive AB Real Estate DevelopmentFinance Part of BONESUPPORT HOLDING AB, Bone Support Incentive AB provides real estate services. The company is based in Lund, Sweden. | Finance |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | Health Technology |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | Technology Services |
Auregen Biotherapeutics, Inc.
Auregen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auregen Biotherapeutics, Inc. provides biotechnology services. The CEO of the American company is Richard John Davies. | Commercial Services |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Health Technology |
